Literature DB >> 19038465

Reference pricing and firms' pricing strategies.

Marisa Miraldo1.   

Abstract

Within a horizontal differentiation model and allowing for heterogeneous qualities, we analyze the effects of reference pricing reimbursement on firms' pricing strategies. With this analysis we find inherent incentives for firms' pricing behavior, and consequently we shed some light on the time consistency of such policy. The analysis encompasses different reference price rules: (i) reference price as the minimum of the observed prices in the market, (ii) reference price as a linear combination of firms' prices. Results show that under the "minimum policy" firms are not able to coordinate on higher prices while the "linear policy", implicitly, provides a coordination device. We have also found that, relatively to the "linear policy", when the reference price is the minimum of observed prices, after policy implementation, total and private expenditures are higher and consumer surplus and firms' profits are lower. With quality differentiation both the minimum and linear policies unambiguously lead to higher prices.

Mesh:

Substances:

Year:  2008        PMID: 19038465     DOI: 10.1016/j.jhealeco.2008.09.006

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  11 in total

Review 1.  Effects of reference pricing in pharmaceutical markets: a review.

Authors:  Matteo Maria Galizzi; Simone Ghislandi; Marisa Miraldo
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

2.  The effects of rebate contracts on the health care system.

Authors:  Julia Graf
Journal:  Eur J Health Econ       Date:  2013-06-23

3.  A simulation model to evaluate pharmaceutical supply chain costs in hospitals: the case of a Colombian hospital.

Authors:  Carlos Franco
Journal:  Daru       Date:  2018-12-18       Impact factor: 3.117

4.  Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?

Authors:  David Granlund; Miyase Yesim Koksal-Ayhan
Journal:  Eur J Health Econ       Date:  2014-11-18

5.  Endogenous versus exogenous generic reference pricing for pharmaceuticals.

Authors:  F Antoñanzas; C A Juárez-Castelló; R Rodríguez-Ibeas
Journal:  Int J Health Econ Manag       Date:  2017-05-15

6.  Reference pricing in the presence of pseudo-generics.

Authors:  Ricardo Gonçalves; Vasco Rodrigues; Hélder Vasconcelos
Journal:  Int J Health Econ Manag       Date:  2015-02-01

7.  The impact of generic reference pricing in Italy, a decade on.

Authors:  Simone Ghislandi; Patrizio Armeni; Claudio Jommi
Journal:  Eur J Health Econ       Date:  2012-11-25

8.  Compulsory licensing and access to drugs.

Authors:  Charitini Stavropoulou; Tommaso Valletti
Journal:  Eur J Health Econ       Date:  2014-01-10

9.  Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs' reimbursements.

Authors:  Eduardo Costa; Carolina Santos
Journal:  Eur J Health Econ       Date:  2022-02-22

10.  Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.

Authors:  N Maniadakis; G Kourlaba; J Shen; A Holtorf
Journal:  BMC Health Serv Res       Date:  2017-05-25       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.